Prediction
Answer Options
This market resolves to “Yes” if Eli Lilly enters into a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date at 11:59 PM Korea Standard Time. Otherwise, it resolves to “No.” Only a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement that gives Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements do not qualify. Extensions of the existing Technology Evaluation Agreement, as well as any other non-binding agreements or agreements that do not grant Eli Lilly direct commercial rights to SmartDepot, will also not qualify. The primary resolution source will be official information from Eli Lilly and Peptron. A consensus of credible reporting may also be used.
Reported by @ScienceofPD